Paydirt
MZ
Insider

Mahkam Zanganeh

Co-Chief Executive Officer

Mahkam Zanganeh (Co-Chief Executive Officer) filed 3 Form 4 reports in the trailing twelve months (3 purchases, 0 sales), most often in Summit Therapeutics Inc. (SMMT). Across 3 priced purchase filings, the average 21-session return was +3.3% from execution and +4.0% from disclosure (delay-adjusted; derived). The largest single filing was $50.0M of SMMT (3,810,000 sh × $13.12, as filed), executed Jun 12.

Add to watchlist
Return, ttmiAverage return per filing, trailing twelve months
+3.3%
avg across 3 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+4.0%
same 3 filings, from disclosure
Filings, ttm
3
3 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$51.9M
shares × price, as filed
Last traded
Jun 12
Filed Jun 12

Median ADV $66.4M across their filed names

Open performance
Volume by month
$51.4M$25.7M$0Oct 2024Apr 2025Oct 2025Apr 2026Sep 2025 · buys $5.9MOct 2025 · buys $500KJun 2026 · buys $51.4M
Buys $57.8M Sells $0

Shares × price, as filed · by filing month · past 24 months

Sectors filed on
Healthcare 3 filings

Sector per market data · by filing · past 12 months

Most traded names
SMMT Summit Therapeutics Inc. SMMT · 4 buys · 0 sells 4 filings
Recent filings
SMMTPURCHASE Summit Therapeutics Inc. View filing → $50.0M
3,810,000 sh × $13.12
Exec Jun 12
Filed Jun 12 · 2:35 PM ET
SMMTPURCHASE Summit Therapeutics Inc. View filing → $1.5M
100,000 sh × $14.60
Exec Jun 4
Filed Jun 4 · 5:45 PM ET
SMMTPURCHASE Summit Therapeutics Inc. View filing → $500K
26,680 sh × $18.74
Exec Oct 21 2025
Filed Oct 23 2025 · 4:06 PM ET
SMMTPURCHASE Summit Therapeutics Inc. View filing → $5.9M
333,394 sh × $17.68
Exec Sep 10 2025
Filed Sep 11 2025 · 7:36 PM ET